NeuroDerm specializes in integrating proprietary pharmaceutical formulations, state-of-the-art delivery system, and digital health solutions with the aim of reducing disease burden and improving the quality of life of patients and their families. NeuroDerm’s flagship product ND0612 is currently in late stage development for Parkinson’s disease patients experiencing motor fluctuations. Its system for self-administered continuous subcutaneous infusion of the gold standard levodopa/carbidopa, was designed specifically to be a user-friendly system for people with Parkinson's disease, to maintain steady therapeutic levodopa plasma concentrations for the purpose of improving fluctuations, that is, reducing patients’ "OFF" time without increasing troublesome dyskinesia. Its tailored solution potentially offers sustained relief (compared to oral immediate-release levodopa/carbidopa treatments) and empowers patients and their families to regain control of their lives with greater daily-life predictability and independence.